Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.
We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.
Moolenburgh
J D
JD
Department of Rheumatology, Medical Centre Alkmaar, Wilhelminalaan 12, 1815JD Alkmaar, The Netherlands. d.moolenburgh@mca.nl
Reinders
M K
MK
Jansen
T L Th A
TL
D006073:Gout / Q000188:drug therapy* / Q000473:pathology; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012219:Rheumatology / Q000379:methods*; D016896:Treatment Outcome; D014503:Urate Oxidase / Q000627:therapeutic use*
D006074:Gout Suppressants; C469709:rasburicase; D014503:Urate Oxidase